Needham analyst Ami Fadia lowered the firm’s price target on Avadel Pharmaceuticals (AVDL) to $19 from $22 and keeps a Buy rating on the shares. The shares “will be under significant pressure” following yesterday’s pre-announcement wherein Q4 Lumryz sales slightly missed consensus, and the 2025 sales outlook of $240M-$260M came in well below the consensus of $290M, the analyst tells investors in a research note. The firm cut estimates but continues to believe the stock is undervalued, even if Lumryz achieves half of management’s peak sales outlook of $1B. Needham still sees “meaningful value” at current Avadel share levels.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Closing Bell Movers: Penguin Solutions up 16% on earnings beat
- Avadel Pharmaceuticals Projects Robust Growth for LUMRYZ
- Avadel Pharmaceuticals sees Q4 revenue $50M, consensus $52.7M
- Avadel Pharmaceuticals sees FY24 revenue $169M, consensus $171.41M
- Avadel Pharmaceuticals sees FY25 revenue $240M-$260M, consensus $291.34M